RougeTx, a preclinical-stage biotechnology company developing first-in-class disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction, today announced its launch with a $58 million Series A financing. The round was co-led by founding investor BioGeneration Ventures (BGV) with Angelini Ventures, together with EIB (European Investment Bank) co-investment facility Aurea, and Kurma Partners, with further participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures.
https://rougetx.com/wp-content/uploads/2026/09/rougetx_logo_colour_RGB.svg00freeflowhttps://rougetx.com/wp-content/uploads/2026/09/rougetx_logo_colour_RGB.svgfreeflow2026-10-06 08:00:292026-10-06 08:00:31RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
RougeTx, a preclinical-stage biotechnology company developing first-in-class disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction, today announced its launch with a $58 million Series A financing. The round was co-led by founding investor BioGeneration Ventures (BGV) with Angelini Ventures, together with EIB (European Investment Bank) co-investment facility Aurea, and Kurma Partners, with further participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures.